Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

InvestingPro analysis indicates net income ... You can also see if ABBV appears on our undervalued or overvalued stock lists. These tools provide a clearer picture of investment opportunities ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a promising investment despite key risks.

NYSE:ABBV Earnings and Revenue History February 21st 2025 Zooming In On AbbVie's Earnings. As finance nerds would already ...

Over the past year, many AbbVie Inc. insiders sold a significant stake in the company which may have piqued investors' ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.